Johnson & Johnson (NYSE:JNJ) took another step toward the exit door for the diabetes business, agreeing to a $2,1 billion offer from private equity shop Platinum Equity for its LifeScan blood glucose monitoring unit.
The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to shutter the Animas insulin pump subsidiary.
Get the full story at our sister site, Drug Delivery Business News.
The post Johnson & Johnson moves closer to exiting the diabetes business with $2.1B LifeScan sale appeared first on MassDevice.
from MassDevice http://ift.tt/2DAvnsY
Cap comentari:
Publica un comentari a l'entrada